GuiZhou SanLi Pharmaceutical (603439) Fundamentals 2026 — P/E 82.6x, Revenue Analysis | SniperIQ
GuiZhou SanLi Pharmaceutical (603439) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥4.0B, trading at ¥9.93 on the SHH. This SniperIQ fundamentals page covers GuiZhou SanLi Pharmaceutical's valuation (P/E 82.6x, P/B 2.7x), profitability (net margin 2.9%), revenue (¥1.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is GuiZhou SanLi Pharmaceutical's market cap?
GuiZhou SanLi Pharmaceutical (603439) has a market capitalization of approximately ¥4.0B, trading at ¥9.93 on the SHH. Market cap moves with the live share price.
What is GuiZhou SanLi Pharmaceutical's P/E ratio?
GuiZhou SanLi Pharmaceutical's trailing twelve-month P/E ratio is 82.6x, with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is GuiZhou SanLi Pharmaceutical?
GuiZhou SanLi Pharmaceutical runs a net profit margin of 2.9%, a gross margin of 71.4%, and an operating margin of 4.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does GuiZhou SanLi Pharmaceutical generate?
GuiZhou SanLi Pharmaceutical reported revenue of ¥1.7B for fiscal year 2025, with net income of ¥46M and earnings per share (EPS) of 0.11. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does GuiZhou SanLi Pharmaceutical pay a dividend?
GuiZhou SanLi Pharmaceutical offers a trailing dividend yield of about 0.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is GuiZhou SanLi Pharmaceutical financially healthy?
GuiZhou SanLi Pharmaceutical carries a debt-to-equity ratio of 0.43x and a current ratio of 1.57x, with a market beta of 0.98. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is GuiZhou SanLi Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For GuiZhou SanLi Pharmaceutical (603439) the key facts are: market cap ¥4.0B, P/E 82.6x, revenue ¥1.7B, 52-week range 9.51-17.46. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track GuiZhou SanLi Pharmaceutical's full fundamentals live
Get GuiZhou SanLi Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.